吸入布地奈德混悬液治疗62例小儿支原体肺炎的临床观察

Clinical observation of inhaled budesonide treatment of 62 cases of mycoplasma pneumonia

目的探讨吸入布地奈德混悬液治疗小儿支原体肺炎的临床疗效。方法将2009年3月～2012年1月在笔者所在医院进行治疗的124例支原体肺炎患儿按治疗方法分为两组。对照组62例,给予静脉滴入红霉素等常规治疗;治疗组62例,在常规治疗的基础上给予吸入布地奈德混悬液治疗。治疗后观察两组的临床疗效和观察指标变化。结果经过治疗,治疗组总有效率为95.16%,显著高于对照组的83.87%,差异有统计学意义(P<0.05);治疗组的住院时间、啰音消失时间、止咳时间、退热时间均明显少于对照组,差异有统计学意义(P<0.01)。结论吸入布地奈德混悬液治疗小儿支原体肺炎的临床疗效显著,具有推广价值。

Objective To investigate clinical efficacy of inhaled budesonide treatment of mycoplasma pneumonia. Methods 124 patients with mycoplasma pneumonia were divided into the control group（62 cases）,treated by conventional treatments such as intravenous infusion of erythromycin and the treatment group（62 cases）,treated by inhaled budesonide treatment on the basis of conventional treatment. Results After the treatment,the total effective rate of the treatment group（95.16%）was significantly higher than that in the control group（83.87%）,（P 〈 0.05）;Hospitalization time, rales disappeared,cough,fever clearance time of the treatment group were less than that of the control group（P 〈 0.01）. Conclusion The clinical efficacy of inhaled budesonide treatment of mycoplasma pneumonia is significant.